Y.S.P.SOUTHEAST ASIA HOLDING
KLSE (MYR): YSPSAH (7178)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
2.26
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
| Date | Old | New | View |
|---|
Discussions
6 people like this. Showing 50 of 2,088 comments
Guide to Investing in Bursa Healthcare 2022
1. Kotra Industries 2. YSP 3. ???
2022-04-02 21:53
Buy-side has no more idea. They will pump all the healthcare stocks remaining
2022-11-04 11:22
walao ehh..wat happen to YSP
Suddenly surge to fly so high today!! Happy Happy
2022-12-13 12:48
Finally this share has released it's true potential power. I have been waiting years for it to shine
2023-01-03 19:55
Apex Healthcare + YSP + Kotra Industries = Dream Healthcare Portfolio 2023
2023-02-23 16:34
Integrity. Intelligent. Industrious. 3iii (iiinvestsmart)$â¬Â£Â¥
Security LastPr PE DY% Divcts ROE ttm-marg
YSPSAH (Pharmaceuticals) 2.35 9.63 3.4 8 9.25 10.3
2023-03-30 17:12
New Production line is started to be operated for the newly acquired factory premise. With the newly operated production line, the company's Revenue YoY % growth will be significantly increased within 2 years.
2024-05-22 18:51
Hi BullishMarket, from where you aware that New Production line is started to be operated for the newly acquired factory premise?
2024-05-22 20:15
bought a few at 2.85, acceptable bargain I think considering today open at RM3
2024-05-23 11:41
https://www.facebook.com/xngyuan/videos/828026755888524?idorvanity=3251240861803724
chenjian sifu commented YSPSAH positively
2024-06-03 22:07
reasons to buy:
1. recorded highest revenue and profit in 20years
2. organic growth, hold patents (expect to continue deliver good result)
3. DY 3.5% above RM0.11 ex 24/6/24
let's monitor
😎
2024-06-04 15:45
Yspsah has been all the while being the lowest valuation company against its peers like Ahealth & Dpharma.
2024-06-06 10:44
https://www.ctee.com.tw/news/20220714700772-439801
永信東南亞控股是台灣本土學名藥製藥廠中，第一家跨國上市的公司。這兩年，受疫情影響，年營收成長仍有3％〜5％。即將來臨的後疫情時代，李芳信預計，自2022年起，公司營收至少有雙位數以上的成長。
2024-07-04 13:57
sold all YSPSAH at open price of 2.35 after very disaapointing QR (9.00am, 21 august 2024)
2024-08-21 09:15
For the first half of 2024, the Group's revenue rose 5.5% to RM184.8 million compared to RM175.2 million reported in the same period last year. The Group's profit before tax for 1H24 declined 17.0% to RM26.0 million from RM31.3 million in 1H23 due to higher unrealised foreign exchange loss was recorded resulted from strengthening of US Dollar.
Therefore, does that mean the stronger ringgit is in favour of YSP?
2024-08-21 14:51
For the first half of 2023, the Group recorded a profit before tax of RM31.3 million compared to RM24.4 million in the same period last year mainly due to higher sales
from domestic and overseas market and foreign exchange gain resulted from weakening of the Ringgit against the US Dollar.
--Q2 2023😁
2024-08-23 15:13
Katara, thanks! I guess it depends on the mix/geography of the sales. Anyway, good to see seriously buyback this round by Lees.
2 months ago
Q32024 quarter report: foreign exchange loss or (gain): (12,511)... This indicates 12 million of forex gain? But in their comments, they mentioned forex loss. The edge also mentioned 12 million forex loss.. (https://theedgemalaysia.com/node/734404)
Kinda confusing. Any comments guys?
3 days ago
In page 2 of 3QQR-2024, they indicate 12 million of forex gain.. Quite confusing.. Dunno it is typo or what
1 day ago
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
1
Koon Yew Yin's Blog
Why all plantation companies will continue to report more profit - Koon Yew Yin
2
3
4
5
Good Articles to Share
6
8
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
maska
more medicine supply
2022-01-24 15:46